Recon: J&J’s Spravato gets FDA approval for depression monotherapy; Chinese biotechs encroach on US drugmakers' dominance
ReconJason Scott
AsiaBiologics/ biosimilars/ vaccinesEuropeMedical DevicesPharmaceuticalsRegulatory Intelligence/PolicyUnited States